Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Array Biopharma

Evaluate

Thumbnail
August 27, 2019

Six burning Otezla questions

Planned divestment of Celgene’s psoriasis blockbuster means instant cashback for Bristol, a result the markets see as a win-win-win.

Thumbnail
August 02, 2019

Upcoming events – Atara and Aslan await validating results

Atara tackles multiple sclerosis’s virus hypothesis while Aslan needs to roar with crucial biliary tract cancer data.

Article image
Vantage logo
July 31, 2019

Amgen pumps up Mirati some more

Article image
Vantage logo
July 25, 2019

Roche pushes pipeline as US biosimilars hit

Article image
Vantage logo
July 05, 2019

Cannabis, M&A and data spur strong gains among small and midcaps

The usual story of positive data and clinical failure influencing company stock performance was given added interest in the second quarter with price fixing allegations…

Article image
Vantage logo
June 18, 2019

Array-size deals don’t come around too often

Pfizer’s Array buyout ranks as 2019’s second largest, but the price sits in a lonely space in the deal universe.

Article image
Vantage logo
June 17, 2019

Rich recognition finally arrives for Array

Pfizer launches an $11.4bn bid for the prolific originator of small molecules, and predicts blockbuster sales in colorectal cancer to help justify the price. 

Article image
Vantage logo
June 05, 2019

Asco 2019 event analyser – low-key meeting belies some huge stock moves

Mirati Therapeutics nearly stole the show at Asco despite not actually presenting – a fact that illustrates how low on meaningful data this year's conference was.

Article image
Vantage logo
May 22, 2019

Colorectal cancer could see Array stand alone at last

The group’s Braftovi/Mektovi combo shows the potential of a targeted approach in colorectal cancer, so where is the competition?

Article image
Vantage logo
May 08, 2019

Astra and Daiichi lay out their plan for a better Herceptin

The companies’ DS-8201 succeeds in breast cancer patients who had failed Kadcyla, and will go before the regulators later this year.

Article image
Vantage logo
April 30, 2019

Lilly scraps two research assets, leaving few rivals behind

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up